TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17284743

Group type: EXPERIMENTAL
Intervention: Labeled heme iron (2 mg as hemoglobin)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Labeled heme iron (4 mg as hemoglobin)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Labeled heme iron (8 mg as hemoglobin)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Zinc intake (1 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Zinc intake (9 mg)
Number of subjects: 48
Study: 16547384

Group type: EXPERIMENTAL
Intervention: Antithrombin activity
Number of subjects: 179

Group type: COMPARATOR
Intervention: Protein C level
Number of subjects: 179

Group type: COMPARATOR
Intervention: TAT concentration
Number of subjects: 179

Group type: COMPARATOR
Intervention: Fibrinogen concentration
Number of subjects: 179
Study: 12064684

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 11833583

Group type: EXPERIMENTAL
Intervention: AZT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7741186

Group type: EXPERIMENTAL
Intervention: Budesonide (Pulmicort; 200 micrograms twice daily)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Long-acting theophylline (Theodur; 200 mg twice daily)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Combination therapy (Budesonide + Theophylline)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Budesonide and Combination therapy
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 61
Study: 2044783

Group type: EXPERIMENTAL
Intervention: HAL + PI of 5-FU
Number of subjects: 74

Group type: COMPARATOR
Intervention: HAL alone
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 74
Study: 7234840

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Antacids
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cimetidine and Antacids (for isolated antral ulcer)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cimetidine (for primary gastric ulcer)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Antacids (for primary duodenal ulcer)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Secondary ulcer treatment
Number of subjects: 32
Study: 31626833

Group type: EXPERIMENTAL
Intervention: Pictorial health warning label on SSBs
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Calorie information label on all drinks
Number of subjects: 401

Group type: COMPARATOR
Intervention: No additional label
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Lower SEP participants
Number of subjects: 401
Study: 31477140

Group type: EXPERIMENTAL
Intervention: Uterine fibroid Option Grid PDAs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre-implementation phase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active implementation phase
Number of subjects: 0
Study: 26775811

Group type: EXPERIMENTAL
Intervention: Verbal reporting to female experimenter
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verbal reporting to male experimenter
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Typed narratives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verbal reporting
Number of subjects: 0
Study: 25935584

Group type: EXPERIMENTAL
Intervention: Slowly progressive weight lifting
Number of subjects: 295

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 295
Study: 23393176

Group type: EXPERIMENTAL
Intervention: Leptin (iv bolus)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (iv bolus)
Number of subjects: 12
Study: 21365183

Group type: EXPERIMENTAL
Intervention: Verbal estimates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Locomotor judgments
Number of subjects: 0
Study: 19685114

Group type: EXPERIMENTAL
Intervention: 10 mg bupivacaine (group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 4 mg bupivacaine plus 25 microg fentanyl (group BF)
Number of subjects: 40
Study: 17898396

Group type: EXPERIMENTAL
Intervention: 70% oxygen
Number of subjects: 0

Group type: COMPARATOR
Intervention: 21% oxygen (medical air)
Number of subjects: 0
Study: 15258014

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% jelly
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sub-Tenon's anaesthesia with lidocaine 2%
Number of subjects: 59
Study: 11532560

Group type: EXPERIMENTAL
Intervention: Phalen sign
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Tinel sign
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Wrist extension test
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Pressure provocation test
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Combination of signs
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: All signs
Number of subjects: 179
Study: 9364289

Group type: EXPERIMENTAL
Intervention: gamma-linolenic acid (C18:3 n‐6) at a dosage of 274 mg twice a day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 7966806

Group type: EXPERIMENTAL
Intervention: RT‐15 Valsalva
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standing cuff
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All methods
Number of subjects: 30
Study: 3296962

Group type: EXPERIMENTAL
Intervention: 10 g carbohydrate supplement
Number of subjects: 102

Group type: COMPARATOR
Intervention: No carbohydrate supplement (control group)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Twice daily insulin
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Once daily insulin
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Blood glucose measurement at 2200 h
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Blood glucose measurement at 0800 h
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Glycosylated haemoglobin concentration in children on twice daily insulin with nocturnal hypoglycaemia
Number of subjects: 102
Study: 31766076

Group type: EXPERIMENTAL
Intervention: Basic information about FSAs delivered via an emailed employee newsletter
Number of subjects: 11000

Group type: EXPERIMENTAL
Intervention: Statements about the absolute returns offered by the accounts
Number of subjects: 11000

Group type: EXPERIMENTAL
Intervention: Statements about the relative returns offered by the accounts
Number of subjects: 11000
Study: 29846653

Group type: EXPERIMENTAL
Intervention: DHA (2.7 g/d)
Number of subjects: 154

Group type: COMPARATOR
Intervention: EPA (2.7 g/d)
Number of subjects: 154
Study: 27140204

Group type: EXPERIMENTAL
Intervention: In-hospital physician-assessed dyspnea
Number of subjects: 1567

Group type: EXPERIMENTAL
Intervention: Patient-reported early dyspnea relief
Number of subjects: 1567

Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire score
Number of subjects: 1567

Group type: EXPERIMENTAL
Intervention: All-cause mortality
Number of subjects: 1567

Group type: EXPERIMENTAL
Intervention: All-cause hospitalization
Number of subjects: 1567

Group type: EXPERIMENTAL
Intervention: Physician-assessed and patient-reported dyspnea
Number of subjects: 1567
Study: 25764960

Group type: EXPERIMENTAL
Intervention: Extracellular matrix (ECM)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Human fibroblast-derived dermal substitute (HFDS)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cost per DFU treatment for ECM
Number of subjects: 26

Group type: COMPARATOR
Intervention: Cost per DFU treatment for HFDS
Number of subjects: 26

Group type: COMPARATOR
Intervention: Total treatment costs comparison
Number of subjects: 26

Group type: COMPARATOR
Intervention: Cost of care for two applications of HFDS
Number of subjects: 26
Study: 24000921

Group type: EXPERIMENTAL
Intervention: Nurse-led smoking cessation intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New electronic medical record-based systems for identifying parents who smoke
Number of subjects: 0
Study: 20634478

Group type: EXPERIMENTAL
Intervention: Interventional management of unbled brain arteriovenous malformations
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (natural history)
Number of subjects: 124
Study: 18258332

Group type: EXPERIMENTAL
Intervention: Solo learning condition (n = 65)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Couple learning condition (n = 65)
Number of subjects: 130
Study: 16842390

Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fexofenadine 120 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 14559409

Group type: EXPERIMENTAL
Intervention: 50% reliable collision alarms
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 75% reliable collision alarms
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 100% reliable collision alarms
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Spatially generated collision alarms (50% reliability)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Spatially generated collision alarms (75% reliability)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Spatially generated collision alarms (100% reliability)
Number of subjects: 70
Study: 10937984

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 471

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 471
Study: 8906009

Group type: EXPERIMENTAL
Intervention: Yuzpe regimen (0.5 mg levonorgestrel and 0.1 mg ethinylestradiol)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Danazol (600 mg orally, repeated after 12 hours)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control cycle (no treatment)
Number of subjects: 32
Study: 1925837

Group type: EXPERIMENTAL
Intervention: Prazosin (2 mg, increased to 4, 10, and 20 mg)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg, increased to 10, 20, and 40 mg)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 6626435

Group type: EXPERIMENTAL
Intervention: Dipyridamole 400 mg/day
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Dipyridamole (2 or 20 micrograms/ml) in vitro
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Dipyridamole added to stored cells
Number of subjects: 6
Study: 3936528

Group type: EXPERIMENTAL
Intervention: halothane
Number of subjects: 66

Group type: COMPARATOR
Intervention: alfentanil
Number of subjects: 66
Study: 30558054

Group type: EXPERIMENTAL
Intervention: Controlled Attenuation Parameter (CAP)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Change in CAP after treatment
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Change in CAP >38 dB/m
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Change in CAP <38 dB/m
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Change in CAP
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Cohen's kappa value
Number of subjects: 65
Study: 27651323

Group type: EXPERIMENTAL
Intervention: Erdosteine (600 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 24156617

Group type: EXPERIMENTAL
Intervention: 20 μg ethinyl estradiol (EE) and 100 μg levonorgestrel (LNG) OCs
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 30 μg EE and 150 μg LNG OCs
Number of subjects: 150
Study: 22717828

Group type: EXPERIMENTAL
Intervention: 36-mm femoral head articulation
Number of subjects: 644

Group type: COMPARATOR
Intervention: 28-mm femoral head articulation
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: 36-mm femoral head articulation (primary arthroplasty)
Number of subjects: 644

Group type: COMPARATOR
Intervention: 28-mm femoral head articulation (primary arthroplasty)
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: 36-mm femoral head articulation (revision arthroplasty)
Number of subjects: 644

Group type: COMPARATOR
Intervention: 28-mm femoral head articulation (revision arthroplasty)
Number of subjects: 644
Study: 20149953

Group type: EXPERIMENTAL
Intervention: Decision Aid (DA)
Number of subjects: 321
Study: 18841784

Group type: EXPERIMENTAL
Intervention: Teacher tablets for 7 days
Number of subjects: 136

Group type: COMPARATOR
Intervention: Qinlian capsule for 7 days
Number of subjects: 136
Study: 15714120

Group type: EXPERIMENTAL
Intervention: Intralesional bleomycin + EPT
Number of subjects: 19

Group type: COMPARATOR
Intervention: Intralesional bleomycin alone
Number of subjects: 19
Study: 12687806

Group type: EXPERIMENTAL
Intervention: Biventricular pacing (Biv‐P) in wide QRS group (n=128)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Biventricular pacing (Biv‐P) in narrow QRS group (n=30)
Number of subjects: 158
Study: 10503854

Group type: EXPERIMENTAL
Intervention: High volume hydration (16-17 mL/kg)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Low volume hydration (1-2 mL/kg)
Number of subjects: 77
Study: 8983875

Group type: EXPERIMENTAL
Intervention: Dopamine infusion
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Amino acids infusion
Number of subjects: 16
Study: 1901635

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of angiotensin II (AII)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (saline) infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AII infusion
Number of subjects: 0
Study: 6292013

Group type: EXPERIMENTAL
Intervention: Naloxone (0.4 mg/min) infusion for 5 minutes before and 20 minutes after intravenous glucose (0.5 g/kg body weight)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 8
Study: 31944628

Group type: EXPERIMENTAL
Intervention: SZC 5 g once-daily during maintenance phase (MP)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: SZC 10 g once-daily during maintenance phase (MP)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Placebo during maintenance phase (MP)
Number of subjects: 267
Study: 31642037

Group type: EXPERIMENTAL
Intervention: Brexanolone injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0
Study: 28753179

Group type: EXPERIMENTAL
Intervention: Targeted feeding intervention incorporating operant conditioning or systematic desensitization with immersive parent training.
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Intensive intervention (10 sessions in a week) for MC group.
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Weekly intervention (10 sessions during 10 weeks) for MC group.
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Both therapy protocols (operant conditioning and systematic desensitization).
Number of subjects: 98
Study: 25694509

Group type: EXPERIMENTAL
Intervention: High sensitivity troponin T (HsTnT) at baseline
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: High sensitivity troponin T (HsTnT) after 24h
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: High sensitivity troponin T (HsTnT) after 72h
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: Killip Class >1
Number of subjects: 830
Study: 25159236

Group type: EXPERIMENTAL
Intervention: Immediate open repair
Number of subjects: 2226

Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 2226
Study: 22297597

Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal therapy (NSPT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Gingivitis group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Periodontitis group
Number of subjects: 30
Study: 20191922

Group type: EXPERIMENTAL
Intervention: Internet-based recruitment strategies including generalized mailings and personalized strategies such as personal office visits, letters, and faxes.
Number of subjects: 205

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 205
Study: 17565476

Group type: EXPERIMENTAL
Intervention: Port stapling using the 'Velocity' device
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional titanium‐port implantation
Number of subjects: 23
Study: 16215308

Group type: EXPERIMENTAL
Intervention: Diethylstilboestrol (DES) 1 mg/day with 75 mg of aspirin
Number of subjects: 58

Group type: COMPARATOR
Intervention: Bicalutamide 50 mg/day
Number of subjects: 58
Study: 11498451

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg daily for 1 month)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Serum from raloxifene phase
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo phase
Number of subjects: 6
Study: 9778008

Group type: EXPERIMENTAL
Intervention: Deep cervical plexus block with 20 ml bupivacaine, 0.375%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Superficial cervical plexus block with 20 ml bupivacaine, 0.375%
Number of subjects: 40
Study: 8164824

Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone per day
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 4 mg dexamethasone per day
Number of subjects: 96

Group type: COMPARATOR
Intervention: 16 mg dexamethasone per day
Number of subjects: 96
Study: 3408828

Group type: EXPERIMENTAL
Intervention: Epidural injection of 80 mg methylprednisolone in 10 ml physiological saline
Number of subjects: 39

Group type: COMPARATOR
Intervention: Interspinous injection of 2 ml physiological saline
Number of subjects: 39
Study: 31353217

Group type: EXPERIMENTAL
Intervention: Intermittent Preventive Treatment (IPT) with dihydroartemisinin-piperaquine (4 and 18 mg/kg per day)
Number of subjects: 2279

Group type: EXPERIMENTAL
Intervention: Intermittent Screening and Treatment (IST) with monthly malaria rapid diagnostic tests
Number of subjects: 2279

Group type: COMPARATOR
Intervention: Single Screening and Treatment (SST)
Number of subjects: 2279
Study: 28839342

Group type: EXPERIMENTAL
Intervention: VBZ 80 mg
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: VBZ 40 mg
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 205
Study: 25355243

Group type: EXPERIMENTAL
Intervention: Spironolactone (MR-blockade)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 101
Study: 24266552

Group type: EXPERIMENTAL
Intervention: Active analgesic strategy with pre-medication with oral midazolam mixture and intravenous alfentanil and midazolam regularly administered during the procedure
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard treatment with morphine and diazepam (control group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) ablation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cryo balloon ablation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Gender differences in pain perception
Number of subjects: 80
Study: 20685015

Group type: EXPERIMENTAL
Intervention: Casein protein meal (CAPM)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Soy protein meal (SOPM)
Number of subjects: 22
Study: 19674901

Group type: EXPERIMENTAL
Intervention: Lower Body Positive Pressure (LBPP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Harness system (LiteGait)
Number of subjects: 12
Study: 17598698

Group type: EXPERIMENTAL
Intervention: Domperidone (test)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Commercially available original preparation (reference)
Number of subjects: 36
Study: 15488867

Group type: EXPERIMENTAL
Intervention: Decrease in triglycerides (n=19, median: -18 mg/dl)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Increase in triglycerides (n=20, median: +44 mg/dl)
Number of subjects: 39
Study: 11125269

Group type: EXPERIMENTAL
Intervention: Topical 0.1% indomethacin solution
Number of subjects: 145

Group type: COMPARATOR
Intervention: Topical 0.1% dexamethasone solution
Number of subjects: 145
Study: 9443652

Group type: EXPERIMENTAL
Intervention: RCU patients (n = 24)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control subjects (n = 12)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: RCU patients (n = 119)
Number of subjects: 155
Study: 8393585

Group type: EXPERIMENTAL
Intervention: Listening to music during gastroscopy
Number of subjects: 32

Group type: COMPARATOR
Intervention: No music during gastroscopy
Number of subjects: 32
Study: 3607096

Group type: EXPERIMENTAL
Intervention: Biofeedback (BF) trained group
Number of subjects: 21

Group type: COMPARATOR
Intervention: Deception (DEC) trained group
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nonfeedback (NF) trained group
Number of subjects: 21
Study: 31416797

Group type: EXPERIMENTAL
Intervention: Severe acute sleep restriction (4 hours time in bed for 5 nights)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Mild long-term sleep restriction (1.5 hours less sleep/night for 6 weeks)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Habitual sleep (9 hours time in bed for 5 nights in study 1; normal sleep duration in study 2)
Number of subjects: 27
Study: 30051267

Group type: EXPERIMENTAL
Intervention: Time trade-off (TTO) technique
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discrete-choice experiment (DCE) technique
Number of subjects: 0
Study: 27871603

Group type: EXPERIMENTAL
Intervention: Prophylactic infusion of phenylephrine (100-μg/mL solution at 1 mL/min)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (0.9% isotonic sodium chloride solution)
Number of subjects: 54
Study: 24150200

Group type: EXPERIMENTAL
Intervention: Ca+MZn+D group (zinc, 15 mg/day + multivitamins; calcium, 500 mg/day; vitamin D, 30,000 IU/3 months)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Ca+D group (calcium, 500 mg/day; vitamin D, 30,000 IU/3 months)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: M+D group (multivitamins; vitamin D, 30,000 IU/3 months)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Ca+MZn+D group
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: M+D group
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Ca+D group
Number of subjects: 119
Study: 22486143

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.5 mg/kg i.v. and Ketamine 0.5 mg/kg i.v. (Group KD)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Dexamethasone 0.5 mg/kg i.v. (Group D)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Ketamine 0.5 mg/kg i.v. (Group K)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Saline (Group C)
Number of subjects: 120
Study: 20649409

Group type: EXPERIMENTAL
Intervention: Oral azithromycin (6 biannual mass distributions)
Number of subjects: 0
Study: 19011472

Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone (HDMP) therapy (30 mg/kg/d for 3 d then 20 mg/kg/d for 4 d)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone (HDMP) therapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28